Clene Inc. (CLNN)

Currency in USD
3.6800
+0.0100(+0.27%)
Closed·
After Hours
3.68000.0000(0.00%)
·
CLNN Scorecard
Full Analysis
2 analysts have revised their earnings upwards for the upcoming period
CLNN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.54083.7200
52 wk Range
2.28016.9000
Key Statistics
Prev. Close
3.67
Open
3.63
Day's Range
3.5408-3.72
52 wk Range
2.2801-6.9
Volume
49.67K
Average Volume (3m)
92.18K
1-Year Change
-27.27%
Book Value / Share
-0.58
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CLNN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
27.8333
Upside
+656.34%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Clene Inc. News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Clene Inc. Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Compare CLNN to Peers and Sector

Metrics to compare
CLNN
Peers
Sector
Relationship
P/E Ratio
−1.1x−1.1x−0.5x
PEG Ratio
−0.02−0.040.00
Price/Book
−6.6x2.2x2.6x
Price / LTM Sales
94.4x8.9x3.3x
Upside (Analyst Target)
-318.8%43.3%
Fair Value Upside
Unlock16.5%6.9%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 27.8333
(+656.34% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.09 / -0.07
Revenue / Forecast
81.00K / 100.00K
EPS Revisions
Last 90 days

CLNN Income Statement

People Also Watch

247.45
AVAV
-4.68%
2.56
INMB
-8.24%
1.9200
DARE
-5.88%
9.070
CAPR
+12.39%
1.230
CTXR
-4.65%

FAQ

What Stock Exchange Does Clene Trade On?

Clene is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Clene?

The stock symbol for Clene is "CLNN."

What Is the Clene Market Cap?

As of today, Clene market cap is 33.06M.

What Is Clene's Earnings Per Share (TTM)?

The Clene EPS (TTM) is -3.85.

From a Technical Analysis Perspective, Is CLNN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Clene Stock Split?

Clene has split 1 times.

How Many Employees Does Clene Have?

Clene has 76 employees.

What is the current trading status of Clene (CLNN)?

As of 11 Aug 2025, Clene (CLNN) is trading at a price of 3.68, with a previous close of 3.67. The stock has fluctuated within a day range of 3.54 to 3.72, while its 52-week range spans from 2.28 to 6.90.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.